Why should we use MRD assessment post hematopoietic stem cell transplantation?

The virtual AML Hub Satellite Symposium at the 46^th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of experts to discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Charles Craddock, University of Birmingham, Birmingham, UK, presented the topic ‘Why should we use MRD assessment post hematopoietic stem cell transplantation?’

During his talk, Professor Charles Craddock focuses on post-transplant strategies, such as maintenance therapy and donor lymphocyte infusion, to improve transplant outcome in patients with AML. He outlines how MRD-guided treatment decisions can prevent or delay relapse after stem cell transplantation in patients with AML.